Drug Combination Details
| General Information of the Combination (ID: C67776) | |||||
|---|---|---|---|---|---|
| Name | Palmitic acid NP Info | + | Methylseleninic acid Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | DDIT3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | EIF2S1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ERN1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| L-02 | CVCL_6926 | Ovarian cancer | Homo sapiens | |||
| In-vivo Model | For a xenograft model, 2 * 106 HepG2 cells were mixed with 50% Matrigel and injected subcutaneously into the right flank of 6-8 week-old male BALB/c athymic nude mice. | |||||
| Experimental
Result(s) |
PA may be a promising and excellent sensitizer for improving the anticancer effect of MSeA in hepatoma chemotherapy. | |||||
